Drug intelligence / Profile preview

COVID-19 convalescent plasma (UNC Chapel Hill)

Development stage: Unknown
Lead developer: University of North Carolina at Chapel Hill
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

COVID-19 convalescent plasma (CCP) is a biologic therapy derived from the blood of individuals who have recovered from a SARS-CoV-2 infection. This specific investigational product was utilized in the CoronaVirus Inactivating Plasma (CoVIP) study, a Phase 2 clinical trial (NCT04524507) led by the University of North Carolina at Chapel Hill. The plasma contains high titers of neutralizing antibodies that specifically target the SARS-CoV-2 virus, binding to viral surface proteins to prevent host cell entry and facilitate viral clearance. The UNC study was designed to compare the efficacy and safety of standard-titer versus high-titer (neutralizing antibody titers >1:640) plasma in hospitalized patients with early-stage COVID-19 symptoms.

Other names: COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaCCPCoronaVirus Inactivating PlasmaAnti-SARS-CoV-2 neutralizing antibody plasmaAnti-SARS-CoV2 neutralizing antibody plasmaAnti-SARS-CoV 2 neutralizing antibody plasma

Targets

ORF3a (SARS-CoV-2 ORF3a protein)M protein (SARS-CoV-2 membrane protein)N (Nucleocapsid protein)RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on COVID-19 convalescent plasma (UNC Chapel Hill).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID-19 convalescent plasma (UNC Chapel Hill).

Explore the full profile